These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25249588)

  • 21. [Management of toxicity associated with chemotherapy for breast cancer].
    Mukohara T; Mukai H
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():516-22. PubMed ID: 17682204
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses.
    Henk HJ; Becker L; Tan H; Yu J; Kavati A; Naeim A; Deeter R; Barron R
    J Med Econ; 2013; 16(1):160-8. PubMed ID: 23016568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antineoplastic agents and the associated myelosuppressive effects: a review.
    Barreto JN; McCullough KB; Ice LL; Smith JA
    J Pharm Pract; 2014 Oct; 27(5):440-6. PubMed ID: 25147158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hematopoietic growth factors and high-dose chemotherapy: will grams succeed where milligrams fail?
    Demetri GD; Griffin JD
    J Clin Oncol; 1990 May; 8(5):761-4. PubMed ID: 1692086
    [No Abstract]   [Full Text] [Related]  

  • 25. Granulocyte colony-stimulating factors: finding the right indication.
    Lyman GH; Shayne M
    Curr Opin Oncol; 2007 Jul; 19(4):299-307. PubMed ID: 17545791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Myelotoxicity due to chemotherapy in oncology practice].
    Geoffrois L
    Rev Prat; 2006 Nov; 56(18):2009-14. PubMed ID: 17274503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Results of a multicenter, phase-II clinical trial of Dicarbamin used to shield leukopoiesis in cancer patients with immunosuppression due to chemotherapy].
    Garin AM; Gorbunova VA; Bychkov MB; Mindra NV; Stenina MB; Topchieva SV; Treshchalina EM; Chitiia LV; Sdvizhkov AM; Borisov VI; Gurov SN; Gershanovich ML; Makhnova EV; Nebol'sin VE
    Vopr Onkol; 2004; 50(2):184-8. PubMed ID: 15176221
    [No Abstract]   [Full Text] [Related]  

  • 28. Hematopoietic growth factors as supportive therapy for cancer- and chemotherapy-induced conditions.
    Symann M
    Curr Opin Oncol; 1991 Aug; 3(4):648-55. PubMed ID: 1932223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Granulocyte-colony stimulating factors for secondary prevention of leucopenia in patients receiving chemotherapy.
    Lowathanasirikul J; Manusirivithaya S; Tangjitgamol S; Leelahakorn S
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S47-53. PubMed ID: 17726809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.
    Waladkhani AR
    Eur J Cancer Care (Engl); 2004 Sep; 13(4):371-9. PubMed ID: 15305906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk assessment in oncology clinical practice. From risk factors to risk models.
    Lyman GH
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 11):8-13. PubMed ID: 14682113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
    Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
    J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia.
    Ratti M; Tomasello G
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):15-24. PubMed ID: 25409861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.
    Crawford J; George M
    Semin Oncol; 1995 Jun; 22(3 Suppl 7):18-22. PubMed ID: 7541916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity.
    Johnston EM; Crawford J
    Semin Oncol; 1998 Oct; 25(5):552-61. PubMed ID: 9783594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of SOAz.
    Nasca S; Jezekova D; Coninx P; Garbe E; Carpentier Y; Cattan A
    Cancer Treat Rep; 1982 Dec; 66(12):2039-42. PubMed ID: 7139646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myelosuppression and its consequences in elderly patients with cancer.
    Balducci L
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 11):27-32. PubMed ID: 14682116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Growth factors in oncology: effectiveness and prospects].
    Ottmann OG; Hoelzer D
    Praxis (Bern 1994); 1998 Sep; 87(36):1153-9. PubMed ID: 9782744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia.
    Crawford J
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):22-8. PubMed ID: 16736985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.